SEC Contract Filing

Filing Date: 2025-03-18

Document Content:
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>5
<FILENAME>xenetic_ex1031.htm
<DESCRIPTION>CONSULTING AGREEMENT
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exhibit 10.31</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>CERTAIN INFORMATION
IDENTIFIED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS (&ldquo;[***]&rdquo;), HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF
REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>CONSULTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS CONSULTING AGREEMENT (the &ldquo;Agreement&rdquo;),
made this 1st day of January, 2025 (the &ldquo;Engagement Date&rdquo;) is entered into by Xenetic Biosciences, Inc., a Nevada Corporation
(the &ldquo;Company&rdquo;), with an address of 945 Concord Street, Framingham, MA 01701, and Dmitry Genkin, an individual with an address
of [***], hereafter referred to (&ldquo;Consultant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>INTRODUCTION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company desires to retain the services of Consultant
as a consultant to the Company, and Consultant desires to serve as a consultant to the Company. For good and valuable consideration, the
parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Services</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Consultant agrees to provide consulting services relating to the Company&rsquo;s DNase-based oncology therapeutic programs, as
more particularly described in Exhibit A attached hereto and to assist the Company in completing the Key Performance Indicators (KPI&rsquo;s)
as set forth in Exhibit B. The services set forth in Exhibit A and the KPI&rsquo;s set forth in Exhibit B shall constitute obligations
to be completed by Consultant (the &ldquo;Services&rdquo;). In carrying out the Services, Consultant shall work at and under the direction
of the Company&rsquo;s Chief Executive Officer. Consultant shall provide additional services and advice to the Company as reasonably requested
from time to time by the Company&rsquo;s CEO relating to Consultant&rsquo;s areas of experience or expertise, in particular with respect
to the DNase technology for use in cancer (which shall also be included as &ldquo;Services&rdquo;). Consultant shall report to the Company&rsquo;s
Scientific Steering Committee at each regularly scheduled meeting of said committee. In addition, the Consultant will provide an update
on the services delivered and progress toward the KPI&rsquo;s on a quarterly basis to the Company&rsquo;s Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Consultant has a conflict of interest, or potential conflict of interest, with respect to any matter put forth to him as part
of his consultancy, Consultant shall identify to the Company the area where he has a conflict of interest and if requested by the Company,
Consultant shall recuse himself from working on such matters on behalf of the Company and shall recuse himself from the discussion of
such matters with any representative of the Company. Further, Consultant shall provide the Company with written notice related to any
potential future engagement which Consult